Gubra announces discontinuation of development of NPY2R in obesity with Boehringer Ingelheim

Today Gubra announces that Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. No further information has been made available to Gubra.

The other three projects in the successful partnership with Boehringer remain unaffected and continue as planned. This includes the development of the potential first-in-class triple agonist obesity treatment, which was advanced to Phase 1 clinical research in July of this year (NCT06352437) and two pre-clinical assets.

Contacts at Gubra
Media: Sofia Pitt Boserup, [email protected], +45 4188 9586
Investors: Kristian Borbos, [email protected], +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra’s activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See www.gubra.dk for more information.

This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-10-31 11:07 CET.

Attachments
Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Gubra announces discontinuation of development of NYP2 in obesity with Boehringer Ingelheim

Share this page

Jan 15, 2025
Dec 30, 2024
Nov 13, 2024
Nov 13, 2024
Nov 7, 2024
Oct 31, 2024
Sep 6, 2024
Aug 22, 2024

Back to news listing

For further information

Contact us

Gubra

Hørsholm Kongevej 11B
2970 Hørsholm
Denmark

[email protected]
+45 3152 ­2650

Back To Top